Kåberg Martin, Weiland Ola
Department of Medicine Huddinge, Division of Infectious Diseases, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.
The Stockholm Needle Exchange, Stockholm Centre for Dependency Disorders, Stockholm, Sweden.
Liver Int. 2020 Feb;40 Suppl 1:61-66. doi: 10.1111/liv.14352.
In 2016 the WHO set a goal to obtain an 80% reduction in new chronic HCV cases, requiring a level of diagnosis of 90%, treatment coverage of 80% and resulting in a 65% reduction in HCV-related deaths by 2030. This goal is easier to reach in specific populations such as people who inject drugs (PWID), men who have sex with men (MSM) or blood-transfusion recipients before screening for HCV became mandatory and in high-income regions. It is much more difficult to achieve macro-elimination throughout the population especially in low-income areas with underdeveloped infrastructures, a high prevalence of HCV and limited economic resources. To achieve the WHO goals by 2030, awareness of HCV must increase and the cascade of care must be improved and implemented. Diagnostic procedures and treatment should be affordable and universally available. At the end of 2017 fewer than 15 countries were on track to reach these goals by 2030.
2016年，世界卫生组织设定了一个目标，即到2030年将新的慢性丙型肝炎病例减少80%，这要求诊断率达到90%，治疗覆盖率达到80%，从而使丙型肝炎相关死亡人数减少65%。在特定人群中，如注射吸毒者、男男性行为者或在丙型肝炎筛查成为强制要求之前的输血接受者，以及在高收入地区，这一目标更容易实现。要在整个人口中实现宏观消除则困难得多，尤其是在基础设施欠发达、丙型肝炎患病率高且经济资源有限的低收入地区。为了在2030年前实现世界卫生组织的目标，必须提高对丙型肝炎的认识，改善并实施连续护理。诊断程序和治疗应该价格可承受且普遍可及。截至2017年底，只有不到15个国家有望在2030年前实现这些目标。
